{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:55:55Z","timestamp":1790207755193,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T00:00:00Z","timestamp":1744502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T00:00:00Z","timestamp":1744502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s11523-025-01142-8","type":"journal-article","created":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T16:16:53Z","timestamp":1744561013000},"page":"389-403","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Toxicity of Pemigatinib in Advanced Cholangiocarcinoma Harboring FGFR Fusions or Rearrangements: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7531-7817","authenticated-orcid":false,"given":"Erman","family":"Akkus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatime Arzu","family":"Yasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Rimassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Lamarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,13]]},"reference":[{"issue":"9","key":"1142_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557\u201388. https:\/\/doi.org\/10.1038\/s41575-020-0310-z.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"1142_CR2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3390\/diagnostics13020233","volume":"13","author":"DW Shin","year":"2023","unstructured":"Shin DW, Moon S-H, Kim JH. Diagnosis of cholangiocarcinoma. Diagnostics. 2023;13(2):233.","journal-title":"Diagnostics"},{"issue":"10391","key":"1142_CR3","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/s0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853\u201365. https:\/\/doi.org\/10.1016\/s0140-6736(23)00727-4.","journal-title":"Lancet"},{"issue":"8","key":"1142_CR4","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"D-Y Oh","year":"2024","unstructured":"Oh D-Y, He AR, Bouattour M, Okusaka T, Qin S, Chen L-T, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9(8):694\u2013704. https:\/\/doi.org\/10.1016\/S2468-1253(24)00095-5.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"1142_CR5","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/s1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22(5):690\u2013701. https:\/\/doi.org\/10.1016\/s1470-2045(21)00027-9.","journal-title":"Lancet Oncol"},{"key":"1142_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104003","author":"A Vogel","year":"2025","unstructured":"Vogel A, Ducreux M. ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer. ESMO Open. 2025;10(1):104003.\u00a0https:\/\/doi.org\/10.1016\/j.esmoop.2024.104003.","journal-title":"ESMO Open."},{"key":"1142_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082039","author":"S Chakrabarti","year":"2020","unstructured":"Chakrabarti S, Kamgar M, Mahipal A. Targeted therapies in advanced biliary tract cancer: an evolving paradigm. Cancers (Basel). 2020;12(8):2039. https:\/\/doi.org\/10.3390\/cancers12082039.","journal-title":"Cancers (Basel)."},{"key":"1142_CR8","unstructured":"Network NCC: Biliary Tract Cancers, Version 3.2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/btc.pdf Accessed 22 July 2024."},{"issue":"2","key":"1142_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, Kelley RK, Kl\u00fcmpen HJ, Malka D, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127\u201340. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.506.","journal-title":"Ann Oncol"},{"key":"1142_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/po.17.00080","volume":"2","author":"A Jain","year":"2018","unstructured":"Jain A, Borad MJ, Kelley RK, Wang Y, Abdel-Wahab R, Meric-Bernstam F, et al. Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype. JCO Precis Oncol. 2018;2:1\u201312. https:\/\/doi.org\/10.1200\/po.17.00080.","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"1142_CR11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.59793","volume":"16","author":"AM Oprescu Macovei","year":"2024","unstructured":"Oprescu Macovei AM, Venter DP, Makkai GG, Valcea S, Venter MD, Tulin A, et al. Options in targeted therapy for advanced cholangiocarcinoma: a 2024 update. Cureus. 2024;16(5): e59793. https:\/\/doi.org\/10.7759\/cureus.59793.","journal-title":"Cureus."},{"issue":"4_suppl","key":"1142_CR12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1200\/JCO.2022.40.4_suppl.427","volume":"40","author":"MM Javle","year":"2022","unstructured":"Javle MM, Abou-Alfa GK, Macarulla T, Personeni N, Adeva J, Bergamo F, et al. Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Interim results from the phase 2 study FIDES-01. J Clin Oncol. 2022;40(4_suppl):427. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.427.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1142_CR13","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671\u201384. https:\/\/doi.org\/10.1016\/S1470-2045(20)30109-1.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1142_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103488","volume":"9","author":"A Vogel","year":"2024","unstructured":"Vogel A, Sahai V, Hollebecque A, Vaccaro GM, Melisi D, Al Rajabi RM, et al. An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202. ESMO Open. 2024;9(6): 103488. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103488.","journal-title":"ESMO Open."},{"key":"1142_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113587","volume":"200","author":"A Parisi","year":"2024","unstructured":"Parisi A, Delaunay B, Pinterpe G, Hollebecque A, Blanc JF, Bouattour M, et al. Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: a joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies. Eur J Cancer. 2024;200: 113587. https:\/\/doi.org\/10.1016\/j.ejca.2024.113587.","journal-title":"Eur J Cancer"},{"key":"1142_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1142_CR17","unstructured":"Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 3rd Symposium on Systematic Reviews: Beyond the Basics; 2000 Jul 3-5; Oxford, UK. https:\/\/cmr.cochrane.org\/?CRGReportID=2972"},{"issue":"9","key":"1142_CR18","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.jclinepi.2013.03.003","volume":"66","author":"L Hartling","year":"2013","unstructured":"Hartling L, Milne A, Hamm MP, Vandermeer B, Ansari M, Tsertsvadze A, et al. Testing the Newcastle Ottawa Scale showed low reliability between individual reviewers. J Clin Epidemiol. 2013;66(9):982\u201393. https:\/\/doi.org\/10.1016\/j.jclinepi.2013.03.003.","journal-title":"J Clin Epidemiol"},{"key":"1142_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076754","volume":"383","author":"MJ Page","year":"2023","unstructured":"Page MJ, Sterne JAC, Boutron I, Hr\u00f3bjartsson A, Kirkham JJ, Li T, et al. ROB-ME: a tool for assessing risk of bias due to missing evidence in systematic reviews with meta-analysis. BMJ. 2023;383: e076754. https:\/\/doi.org\/10.1136\/bmj-2023-076754.","journal-title":"BMJ"},{"issue":"Suppl 3","key":"1142_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.7861\/fhj.10-3-s26","volume":"10","author":"A Alsinbili","year":"2023","unstructured":"Alsinbili A. Assessing the risk of bias in single-arm trials for systematic reviews: moving towards a more reliable evaluation of clinical evidence. Future Healthc J. 2023;10(Suppl 3):26\u20137. https:\/\/doi.org\/10.7861\/fhj.10-3-s26.","journal-title":"Future Healthc J"},{"issue":"3","key":"1142_CR21","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/biom.12817","volume":"74","author":"L Lin","year":"2018","unstructured":"Lin L, Chu H. Quantifying publication bias in meta-analysis. Biometrics. 2018;74(3):785\u201394. https:\/\/doi.org\/10.1111\/biom.12817.","journal-title":"Biometrics"},{"issue":"4","key":"1142_CR22","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1214\/aoms\/1177729756","volume":"21","author":"MF Freeman","year":"1950","unstructured":"Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Stat. 1950;21(4):607\u201311.","journal-title":"Ann Math Stat"},{"issue":"7","key":"1142_CR23","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1177\/21925682221110527","volume":"12","author":"JR Dettori","year":"2022","unstructured":"Dettori JR, Norvell DC, Chapman JR. Fixed-effect vs random-effects models for meta-analysis: 3 points to consider. Global Spine J. 2022;12(7):1624\u20136. https:\/\/doi.org\/10.1177\/21925682221110527.","journal-title":"Global Spine J."},{"issue":"7414","key":"1142_CR24","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"issue":"5","key":"1142_CR25","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Iannotti NO, Gutierrez M, Smith DC, F\u00e9liz L, Lihou CF, et al. FIGHT-101, a first-in-human study of potent and selective FGFR 1\u20133 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies. Ann Oncol. 2022;33(5):522\u201333. https:\/\/doi.org\/10.1016\/j.annonc.2022.02.001.","journal-title":"Ann Oncol"},{"issue":"6","key":"1142_CR26","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1007\/s10637-023-01396-x","volume":"41","author":"T Deng","year":"2023","unstructured":"Deng T, Zhang L, Shi Y, Bai G, Pan Y, Shen A, et al. Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1\u20133) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial. Invest New Drugs. 2023;41(6):808\u201315. https:\/\/doi.org\/10.1007\/s10637-023-01396-x.","journal-title":"Invest New Drugs"},{"issue":"9","key":"1142_CR27","doi-asserted-by":"publisher","first-page":"10597","DOI":"10.1002\/cam4.5798","volume":"12","author":"Y Fujiwara","year":"2023","unstructured":"Fujiwara Y, Kuboki Y, Furukawa M, Mizuno N, Hara H, Ioka T, et al. FIGHT-102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies. Cancer Med. 2023;12(9):10597\u2013611. https:\/\/doi.org\/10.1002\/cam4.5798.","journal-title":"Cancer Med"},{"issue":"4","key":"1142_CR28","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.1002\/cam4.5273","volume":"12","author":"GM Shi","year":"2023","unstructured":"Shi GM, Huang XY, Wen TF, Song TQ, Kuang M, Mou HB, et al. Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: a phase II study. Cancer Med. 2023;12(4):4137\u201346. https:\/\/doi.org\/10.1002\/cam4.5273.","journal-title":"Cancer Med"},{"key":"1142_CR29","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2023.1197","author":"A Lindley","year":"2024","unstructured":"Lindley A, Prager G, Bitzer M, Burn TC, Lihou CF, Croft E. Global expanded access program for pemigatinib in patients with previously treated locally advanced or metastatic cholangiocarcinoma and fibroblast growth factor receptor gene alterations. Cancer Res Treat. 2024;56(3):847-55.\u00a0https:\/\/doi.org\/10.4143\/crt.2023.1197.","journal-title":"Cancer Res Treat"},{"key":"1142_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02934-7","author":"J Rod\u00f3n","year":"2024","unstructured":"Rod\u00f3n J, Damian S, Furqan M, Garc\u00eda-Donas J, Imai H, Italiano A, et al. Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nat Med. 2024;30(6):1645-54. https:\/\/doi.org\/10.1038\/s41591-024-02934-7.","journal-title":"Nat Med"},{"issue":"3","key":"1142_CR31","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3322\/caac.21825","volume":"74","author":"R Casolino","year":"2024","unstructured":"Casolino R, Beer PA, Chakravarty D, Davis MB, Malapelle U, Mazzarella L, et al. Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance. CA Cancer J Clin. 2024;74(3):264\u201385. https:\/\/doi.org\/10.3322\/caac.21825.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1142_CR32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41698-024-00547-4","volume":"8","author":"EC Anderson","year":"2024","unstructured":"Anderson EC, DiPalazzo J, Lucas FL, Hall MJ, Antov A, Helbig P, et al. Genome-matched treatments and patient outcomes in the Maine Cancer Genomics Initiative (MCGI). NPJ Precis Oncol. 2024;8(1):67. https:\/\/doi.org\/10.1038\/s41698-024-00547-4.","journal-title":"NPJ Precis Oncol."},{"issue":"11","key":"1142_CR33","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/s1470-2045(21)00486-1","volume":"22","author":"C Yoo","year":"2021","unstructured":"Yoo C, Kim KP, Jeong JH, Kim I, Kang MJ, Cheon J, et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol. 2021;22(11):1560\u201372. https:\/\/doi.org\/10.1016\/s1470-2045(21)00486-1.","journal-title":"Lancet Oncol"},{"key":"1142_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2024.05.009","author":"IA Voutsadakis","year":"2024","unstructured":"Voutsadakis IA, Kokkali S, Digklia A. Treatment of metastatic biliary cancers with irinotecan and 5-fluorouracil based chemotherapy after platinum\/gemcitabine progression: a systematic review and meta-analysis. Clin Colorectal Cancer. 2024;23(4):318-325.e1. https:\/\/doi.org\/10.1016\/j.clcc.2024.05.009.","journal-title":"Clin Colorectal Cancer"},{"issue":"4","key":"1142_CR35","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/sj.bjc.6605211","volume":"101","author":"JW Valle","year":"2009","unstructured":"Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer. 2009;101(4):621\u20137. https:\/\/doi.org\/10.1038\/sj.bjc.6605211.","journal-title":"Br J Cancer"},{"issue":"14","key":"1142_CR36","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381. https:\/\/doi.org\/10.1056\/NEJMoa0908721.","journal-title":"N Engl J Med"},{"issue":"8","key":"1142_CR37","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDoa2200015.","journal-title":"NEJM Evid."},{"issue":"16_suppl","key":"1142_CR38","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.1200\/JCO.2024.42.16_suppl.4093","volume":"42","author":"RS Finn","year":"2024","unstructured":"Finn RS, Ueno M, Yoo C, Ren Z, Furuse J, Kelley RK, et al. Three-year follow-up data from KEYNOTE-966: Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem\/cis) compared with gem\/cis alone for patients (pts) with advanced biliary tract cancer (BTC). J Clin Oncol. 2024;42(16_suppl):4093. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4093.","journal-title":"J Clin Oncol"},{"key":"1142_CR39","doi-asserted-by":"publisher","first-page":"S1282","DOI":"10.1016\/j.annonc.2021.08.2082","volume":"32","author":"L Perkhofer","year":"2021","unstructured":"Perkhofer L, Striefler JK, Sinn M, Opitz B, Goetze TO, Gallmeier E, et al. LBA10 Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: Final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group. Ann Oncol. 2021;32:S1282. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.2082.","journal-title":"Ann Oncol"},{"key":"1142_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-079126","volume":"386","author":"A Tibau","year":"2024","unstructured":"Tibau A, Hwang TJ, Avorn J, Kesselheim AS. Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study. BMJ. 2024;386: e079126. https:\/\/doi.org\/10.1136\/bmj-2023-079126.","journal-title":"BMJ"},{"issue":"3","key":"1142_CR41","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388(3):228\u201339. https:\/\/doi.org\/10.1056\/NEJMoa2206834.","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"1142_CR42","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1200\/JCO.2022.40.16_suppl.4009","volume":"40","author":"L Goyal","year":"2022","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, Morizane C, Valle JW, Karasic TB, et al. Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions\/rearrangements. J Clin Oncol. 2022;40(16_suppl):4009. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.4009.","journal-title":"J Clin Oncol"},{"key":"1142_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.11.017","author":"L Goyal","year":"2025","unstructured":"Goyal L, DiToro D, Hollebecque A, Bridgewater JA, Shimura M, Kano A, et al. Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling. Ann Oncol. 2025;36(4):414-25. https:\/\/doi.org\/10.1016\/j.annonc.2024.11.017.","journal-title":"Ann Oncol"},{"issue":"9","key":"1142_CR44","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/bjc.2016.284","volume":"115","author":"SD Kaupp-Roberts","year":"2016","unstructured":"Kaupp-Roberts SD, Yadegarfar G, Friend E, O\u2019Donnell CM, Valle JW, Byrne C, et al. Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder. Br J Cancer. 2016;115(9):1032\u20138. https:\/\/doi.org\/10.1038\/bjc.2016.284.","journal-title":"Br J Cancer"},{"issue":"3_suppl","key":"1142_CR45","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1200\/JCO.2021.39.3_suppl.276","volume":"39","author":"JW Valle","year":"2021","unstructured":"Valle JW, Bibeau K, Cho Y, Ren H, F\u00e9liz L, Lihou CF, et al. Longitudinal evaluation of quality of life (QoL) in patients (Pts) with FGFR2-driven cholangiocarcinoma (CCA) treated with pemigatinib. J Clin Oncol. 2021;39(3_suppl):276. https:\/\/doi.org\/10.1200\/JCO.2021.39.3_suppl.276.","journal-title":"J Clin Oncol"},{"key":"1142_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103091","volume":"155","author":"A Mahipal","year":"2020","unstructured":"Mahipal A, Tella SH, Kommalapati A, Yu J, Kim R. Prevention and treatment of FGFR inhibitor-associated toxicities. Crit Rev Oncol Hematol. 2020;155: 103091. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103091.","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01142-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01142-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01142-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T11:47:35Z","timestamp":1748260055000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01142-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,13]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1142"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01142-8","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,13]]},"assertion":[{"value":"26 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Erman Akkus and Dr. Hatime Arzu Yasar declare that they have no conflicts of interest that might be relevant to the contents of this article. Dr. Lorenza Rimassa reports grant\/research funding (to institution) from AbbVie, AstraZeneca, BeiGene, Exelixis, Fibrogen, Incyte, IPSEN, Jazz Pharmaceuticals, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, TransThera Sciences, and Zymeworks; consulting fees from AbbVie, AstraZeneca, Basilea, Bayer, Bristol Myers Squibb, Eisai, Elevar Therapeutics, Exelixis, Genenta, Hengrui, Incyte, IPSEN, Jazz Pharmaceuticals, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, and Zymeworks; lecture fees from AstraZeneca, Bayer, Bristol Myers Squibb, Guerbet, Incyte, IPSEN, Roche, and Servier; and travel expenses from AstraZeneca and Servier. Dr. Angela Lamarca declares travel and educational support from Ipsen, Pfizer, Bayer, AAA, SirtEx, Novartis, Mylan, Delcath Advanz Pharma and Roche; Speaker honoraria from Merck, Pfizer, Ipsen, Incyte, AAA\/Novartis, QED, Servier, Astra Zeneca, EISAI, Roche, Advanz Pharma and MSD; Advisory and consultancy honoraria from EISAI, Nutricia, Ipsen, QED, Roche, Servier, Boston Scientific, Albireo Pharma, AstraZeneca, Boehringer Ingelheim, GENFIT, TransThera Biosciences, Taiho and MSD; Principal Investigator-associated Institutional Funding form QED, Merck, Boehringer Ingelheim, Servier, Astra Zeneca, GenFit, Panbela Therapeutics, Novocure GmbH, Camurus AB, Albireo Pharma, Taiho, TransThera, Jazz Therapeutics and Roche; Member of the Knowledge Network and NETConnect Initiatives funded by Ipsen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study analyzed publicly available data from published studies. Therefore, ethics approval and informed consent of the patients were not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"All authors have consented to publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"No datasets were generated or analyzed during the current study. The studies from which the data are used for meta-analyses are presented in the article and in the references.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the study's conception and design. EA and AY collected the data. EA and AY performed the analysis. The first draft of the manuscript was written by EA and AY. All authors commented on previous versions of the manuscript, AL and LR repeatedly revised the draft manuscript and supervised the study. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}